NeuroPace today released 7-year follow-up data from a clinical trial of its RNS neurostimulation system designed to prevent epileptic seizures, touting an over-70% reduction in seizure frequency. The company’s RNS system is a closed-loop brain-responsive neurostim system designed for preventing epileptic seizures, and has been approved by the FDA as adjunctive therapy to treat partial […]
NeuroPace
DARPA taps NeuroPace for memory loss trial
Epilepsy treatment devices maker NeuroPace hopes to expand its clinical applications by supporting a research initiative to evaluate neurostimulation implants in treatment of memory deficits.
FLASH: FDA approves NeuroPace’s anti-epilepsy implant
FDA regulators today announced that they granted premarket approval for NeuroPace for its anti-epilepsy device, an implantable neurostimulator that helps prevent seizures.
Second Sight’s ‘bionic eye’ conquers Cleveland Clinic’s ‘Top 10’
Cleveland Clinic this week announced its picks for the top 10 medical innovations of 2014, placing the newly FDA-approved Argus II "bionic eye" from Second Sight in the #1 spot.
The device is a breakthrough for the U.S., designed to restore meaningful eyesight to patients suffering from retinitis pigmentosa, a condition that leaves patients with either bare light perception or none at all. There is currently no cure for the rare condition, which is diagnosed about 250 times each year.
Details on the FDA panel’s NeuroPace deliberations
An FDA advisory panel last week debated who should be allowed to implant NeuroPace’s anti-epilepsy device, where it should be implanted and which patients should be eligible for it on the way to recommending approval for the implant.
The federal watchdog agency’s Neurological Devices Advisory Panel, in a non-binding vote Feb. 22, recommended that the FDA approve NeuroPace’s RNS deep-brain stimulation therapy for certain categories of epilepsy, but had some reservations about the details
FDA panel recommends approval of NeuroPace’s anti-epilepsy implant
California neurostimulation devices maker NeuroPace crept 1 step closer to an FDA win for its epilepsy implant with near-unanimous approval from the FDA’s Neurological Devices Advisory Panel.
NeuroPace’s epilepsy implant lands a date with the FDA after more than 2 years
California medical device maker NeuroPace is finally getting a date with the FDA to review its premarket application for a neuromodulation implant for patients with epilepsy.
NeuroPace filed its application in July 2010 for its RNS System, hoping to win indication as an adjunct therapy for reducing seizures in patients aged 18 and older.
French breast implant scandal chief released from jail | MassDevice.com On Call
MASSDEVICE ON CALL — French medical device CEO Jean-Claude Mas was freed from prison and is awaiting trial after he admitted that he allowed his company to use substandard silicone in breast implants.
NeuroPace set to land at least $49M in latest round | Funding Roundup
NeuroPace, which is developing an implantable device to treat epilepsy and other neurological disorders, is on the verge of closing a large financing round, according to a regulatory filing
The Mountain View, Calif.-based firm has drummed up $49.1 million of a hoped-for $61.9 million round, according to the filing. A slew of names linked to venture capital firms are listed on the filing, from the likes of Kleiner Perkins Caufield & Byers, New Enterprise Associates, Angel Medical Systems, Cutlass Capital and Domain Associates.
NeuroPace set to land at least $49M in latest round
NeuroPace, which is developing an implantable device to treat epilepsy and other neurological disorders, is on the verge of closing a large financing round, according to a regulatory filing
The Mountain View, Calif.-based firm has drummed up $49.1 million of a hoped-for $61.9 million round, according to the filing. A slew of names linked to venture capital firms are listed on the filing, from the likes of Kleiner Perkins Caufield & Byers, New Enterprise Associates, Angel Medical Systems, Cutlass Capital and Domain Associates.
